Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Growth Shares
Where to reinvest your Fortescue (ASX:FMG) dividends
⏸️ Dividend Shares
ASX 200 shares going ex-dividend this week
Healthcare Shares
ASX medical shares report promising half-year results
Share Market News
Leading brokers name 3 ASX shares to sell today
⏸️ ASX Shares
2 strong ASX healthcare shares to buy this month
Healthcare Shares
Is it time to buy these 2 hot ASX healthcare shares?
Share Market News
ASX 200 Weekly Wrap: Friday carnage ruins last week of ASX earnings
Share Market News
3 of the best ASX 200 results from last week
Share Market News
Leading brokers name 3 ASX shares to sell today
⏸️ ASX Shares
Is the Cochlear (ASX:COH) share price in the buy zone?
Share Market News
Why broker downgraded these 2 ASX 200 shares last week
Share Market News
ASX 200 sinks 1.3%, Cochlear soars, TWE sours
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
